Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Relapse

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    3,166 result(s) found for: Relapse. Displaying page 1 of 159.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2006-007022-64 Sponsor Protocol Number: NMSG 16/07 Start Date*: 2007-03-06
    Sponsor Name:Rigshospitalet
    Full Title: Phase II study of bortezomib-dexametason and high-dose melphalan in patients relapsing after high-dose melphalan with autologous stem cell support
    Medical condition: Patients with multiple myeloma earlier treated with high-dose melphalan with autologous stem cell support experiencing their first relapse.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-003809-22 Sponsor Protocol Number: MDS Start Date*: 2022-09-09
    Sponsor Name:Karolinska University Hospital
    Full Title: A phase II multicenter single-armed study using subject-specific minimal residual disease markers to adopt treatment after allogeneic stem cell transplantation for subjects with myelodysplastic syn...
    Medical condition: Myelodysplastic syndrome (MDS)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned) FI (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-001040-31 Sponsor Protocol Number: TUD-RELAZA-008 Start Date*: 2006-11-23
    Sponsor Name:University of Technology Dresden
    Full Title: Treatment of the haematological relapse in patients suffering from acute myeloid leukaemia or myelodysplastic syndrome with 5-Azacytidin (Vidaza®) after hematopoietic stem cell transplantation "REL...
    Medical condition: Patients suffering from acute myeloid leukaemia or myelodysplastic syndrome with falling CD34-chimerism or relapse after hematopoietic stem cell transplantation.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-001150-10 Sponsor Protocol Number: ECU-NMO-301 Start Date*: 2013-12-12
    Sponsor Name:Alexion Pharmaceuticals, Inc.
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF ECULIZUMAB IN PATIENTS WITH RELAPSING NEUROMYELITIS OPTICA (NMO)
    Medical condition: Neuromyelitis Optica
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004852 10029322 Neuromyelitis optica LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) IT (Completed) GB (Prematurely Ended) ES (Completed) AT (Prematurely Ended) CZ (Prematurely Ended) DK (Prematurely Ended) FR (Completed) HR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-003920-30 Sponsor Protocol Number: CHARLY Start Date*: 2016-09-20
    Sponsor Name:University Hospital Heidelberg
    Full Title: Phase-II study on the value of post-transplant Cyclophosphamide after Thiotepa-based haplo-identical stem-cell transplantation for relapsed-refractory lymphoma
    Medical condition: Myeloablative haplo-identical stem cell transplantation for poor risk non-hodgkin lymphoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-002476-92 Sponsor Protocol Number: 20120215 Start Date*: 2015-06-29
    Sponsor Name:Amgen Inc
    Full Title: A Randomized, Open-label, Controlled Phase 3 Trial to Investigate the Efficacy, Safety, and Tolerability of the BiTE® Antibody Blinatumomab as Consolidation Therapy Versus Conventional Consolidatio...
    Medical condition: Patients with Philadelphia chromosome negative (Ph-) high-risk (HR) first relapse B-precursor ALL (as defined by I-BFM SG/IntReALL criteria)
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    21.0 100000004864 10063625 Acute lymphoblastic leukemia recurrent LLT
    21.1 100000004864 10066109 Precursor B-lymphoblastic leukemia acute LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) BE (Completed) IT (Completed) SE (Completed) PT (Completed) DK (Completed) AT (Completed) GB (GB - no longer in EU/EEA) PL (Completed) ES (Ongoing) FR (Completed) NL (Completed) Outside EU/EEA GR (Completed) NO (Completed) HU (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2006-003999-35 Sponsor Protocol Number: Kep-F10.2.01 Start Date*: 2007-01-11
    Sponsor Name:Charité Campus Mitte, Klinik für Psychiatrie und Psychotherapie
    Full Title: Efficacy and safety of levetiracetam in prevention of alcohol relapse in recently detoxified alcohol dependent patients
    Medical condition: detoxified alcohol dependent outpatients
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-005414-18 Sponsor Protocol Number: ZKS000783 Start Date*: 2014-02-18
    Sponsor Name:University Medical Center Freiburg
    Full Title: Thiotepa- Fludarabine- Treosulfan (TFT) conditioning for 2nd allogeneic PBSCT from a different unrelated donor in patients with AML relapsing from prior allogeneic HCT
    Medical condition: Patients with relapse of AML after the 1st allogeneic PBSCT.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10001941 AML LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-001965-34 Sponsor Protocol Number: oral-CORTEM Start Date*: 2012-11-07
    Sponsor Name:Servicio de Neurología, HU. Germans Trias i Pujol
    Full Title: Multicenter, randomized, double-blind clinical trial to compare the clinical and radiological efficacy of 625 mg vs 1250 mg of oral methylprednisolone in patients with multiple sclerosis in relapse.
    Medical condition: Multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    15.0 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-005072-32 Sponsor Protocol Number: R&D2004/39 Start Date*: 2005-12-19
    Sponsor Name:Kings College London (IOP) / South London and Maudsley NHS Trust (Co-sponsorship)
    Full Title: Is it possible to modify the course of manic relapse? A pilot study of the effectiveness of quetiapine in preventing the development of manic episodes in Bipolar Disorder.
    Medical condition: Bipolar Disorder
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-002640-25 Sponsor Protocol Number: 217-MDD-302 Start Date*: 2019-12-09
    Sponsor Name:Sage Therapeutics, Inc.
    Full Title: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF SAGE-217 WITH FIXED, REPEATED TREATMENT REGIMEN ON RELAPSE PREVENTION IN ADULTS WITH MAJOR DEPRESSIVE DIS...
    Medical condition: MAJOR DEPRESSIVE DISORDER
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004873 10025453 Major depressive disorder NOS LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) ES (Prematurely Ended) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-005439-41 Sponsor Protocol Number: PLRG-10/ML29157 Start Date*: 2017-08-13
    Sponsor Name:Polish Lymphoma Research Group (PLRG)
    Full Title: EVALUATION OF EFFICACY AND SAFETY OF OBINUTUZUMAB PREEMPTIVE TREATMENT AT THE TIME OF THE MOLECULAR RELAPSE AFTER FIRST LINE IMMUNOCHEMOTHERAPY WITH AUTOLOGOUS STEM CELL TRANSPLANTATION IN MANTLE C...
    Medical condition: Molecular relapse after the first line immunochemotherapy with autologous stem cell transplantation in mantle cell lymphoma (MCL) patients
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061275 Mantle cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-003476-39 Sponsor Protocol Number: RG_12-188 Start Date*: 2012-12-04
    Sponsor Name:The University of Birmingham [...]
    1. The University of Birmingham
    2. Manchester University NHS Foundation Trust
    Full Title: Short course daily prednisolone therapy at the time of upper respiratory tract infection in children with relapsing steroid sensitive nephrotic syndrome; the PREDNOS 2 study.
    Medical condition: Relapsing steroid sensitive nephrotic syndrome
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2016-002820-10 Sponsor Protocol Number: 205MS305 Start Date*: 2017-03-13
    Sponsor Name:Biogen Idec Research Limited
    Full Title: A Phase 3b, 12-month, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of BIIB019, Daclizumab, in Subjects with Relapsing-Remitting Multiple Sclerosis (RRMS) Switching from Nataliz...
    Medical condition: Remitting-Relapsing Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) DE (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-002247-16 Sponsor Protocol Number: R092670SCH3005 Start Date*: 2010-03-10
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A 24-month, Prospective, Randomized, Active-Controlled, Open-Label, Rater Blinded, Multicenter, International Study of the Prevention of Relapse Comparing Long-Acting Injectable Paliperidone Palmit...
    Medical condition: Recently diagnosed (1-5 years since diagnosis) schizophrenia.
    Disease: Version SOC Term Classification Code Term Level
    12.0 10039626 Schizophrenia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) HU (Completed) ES (Completed) LT (Completed) BE (Completed) FR (Completed) EE (Completed) IT (Completed) BG (Completed) AT (Completed) GB (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2006-003580-31 Sponsor Protocol Number: MORAb-003-002 Start Date*: 2007-04-23
    Sponsor Name:Morphotek
    Full Title: A Study of the Efficacy of MORAb-003 in Subjects with Platinum-Sensitive Epithelial Ovarian Cancer in First Relapse
    Medical condition: Ovarian cancer in first relapse
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2013-004397-99 Sponsor Protocol Number: MBCC28040 Start Date*: 2014-06-17
    Sponsor Name:Instituto Tecnológico PET, S.A.U. (ITP)
    Full Title: A Phase III Clinical Trial to evidence the safety and efficacy of the radio-drug 18f-Fluorocholine (18F-FCH), using Positron Emission Tomography (PET) for the diagnosis of the prostate carcinoma in...
    Medical condition: Prostate Carcinoma in patients with biochemical relapse.
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2006-002676-18 Sponsor Protocol Number: 26-01 Start Date*: 2006-11-23
    Sponsor Name:WELEDA AG DEUTSCHLAND
    Full Title: Randomized, open-label phase 2 study on post-relapse disease-free survival (PRDFS) with the Viscum-album Extract (VA-E) Iscador P or oral Etoposide in spindle-cell bone-sarcoma patients in complete...
    Medical condition: spindle-cell bone-sarcoma patients in complete remission after surgery for second relapse.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10049067 Spindle cell sarcoma LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-002194-18 Sponsor Protocol Number: CA209-9P9 Start Date*: 2018-03-15
    Sponsor Name:Medical Center - University of Freiburg
    Full Title: Phase 1/2 Trial to determine the Response Rate of Nivolumab in Acute Myeloid Leukemia (AML) relapse after Allogeneic Hematopoietic Cell Transplantation (allo-HCT)
    Medical condition: Acute myeloid leukemia relapse after allo-HCT
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10001941 AML LLT
    20.0 100000004864 10066572 AML progression LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-000940-26 Sponsor Protocol Number: CASM981C2314 Start Date*: 2004-09-24
    Sponsor Name:Novartis Pharma
    Full Title: A 22-week randomized, multicenter, parallel-group, double-blind study to compare a pimecrolimus 1 % (Elidel) twice daily (b.i.d.) maintenance dosing regimen to a once daily (o.d.) maintenance dosin...
    Medical condition: Atopic dermatitis
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FI (Completed) AT (Completed) GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 13 02:36:02 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA